2018 ESC/EACTS Guidelines on myocardial revascularisation
This guideline cites 15 of the 199 landmark trials in our Cardiology register.
- Issued by
- ESC/
EACTS - Year
- 2018
- Source
- Neumann FJ, Sousa-Uva M, et al. Eur Heart J. 2019;40(2):87–165.doi 10.1093/eurheartj/ehy394
The joint ESC/EACTS revascularisation guideline is the procedural companion to the syndrome guidelines: it sets out when to revascularise, how to choose between PCI and surgery in multivessel and left main disease, and how to protect the result with antiplatelet therapy. Only trials published before its 2018 cut-off appear in the sections below — later evidence such as ISCHEMIA, COMPLETE and FAME 3 lives on the chronic and acute coronary syndrome pages.
PCI vs. CABG: multivessel & left main disease4
- 2016EXCELCardiology · Coronary · left main PCIIn 1,905 patients with left main disease of low-to-intermediate complexity, PCI with everolimus-eluting stents was non-inferior for 3-year death, stroke, or MI compared with CABG.15.4% vs 14.7%Read →
- 2016NOBLECardiology · Coronary · left main PCIIn 1,201 patients with unprotected left main coronary disease, PCI with drug-eluting stents increased 5-year death, MI, repeat revascularisation, or stroke compared with CABG.HR 1.4895% CI 1.11-1.96Read →
- 2012FREEDOM 2012Cardiology · Coronary · PCI vs CABGIn 1,900 patients with diabetes and multivessel coronary disease, PCI with drug-eluting stents increased death, nonfatal MI, or nonfatal stroke compared with CABG.26.6% vs 18.7%Read →
- 2009SYNTAX CoreCardiology · Coronary · PCI vs CABGIn 1,800 patients with 3-vessel or left main coronary disease, PCI with paclitaxel-eluting stents increased 12-month death, stroke, MI, or repeat revascularisation compared with CABG.17.8% vs 12.4%Read →
Revascularisation vs. medical therapy in stable disease5
- 2018ORBITACardiology · Coronary · RevascularisationIn 200 patients with stable single-vessel angina, PCI did not improve exercise time at 6 weeks compared with a sham procedure.Read →
- 2016STICHCardiology · HF · CABGIn 1,212 patients with ischaemic cardiomyopathy (EF ≤ 35%) and CAD, coronary-artery bypass grafting plus medical therapy reduced 10-year all-cause mortality compared with medical therapy alone.HR 0.8495% CI 0.73-0.97Read →
- 2012FAME 2Cardiology · Coronary · FFR-guided PCIIn 888 patients with stable coronary disease and a functionally significant (FFR ≤0.80) stenosis, FFR-guided PCI plus medical therapy reduced death, MI, or urgent revascularisation compared with medical therapy alone.HR 0.3295% CI 0.19-0.53Read →
- 2009FAMECardiology · Coronary · RevascularisationIn 1,005 patients with multivessel CAD, FFR-guided PCI reduced MACE at one year versus angiography-guided PCI.13.2% vs 18.3%Read →
- 2007COURAGECardiology · Coronary · RevascularisationIn 2,287 patients with stable coronary artery disease, PCI added to optimal medical therapy did not reduce death or non-fatal MI compared with optimal medical therapy alone.HR 1.05Read →
Revascularisation in acute coronary syndromes2
- 2017CULPRIT-SHOCK CoreICU · CS / MCS · RevascularisationIn 706 patients with multivessel disease and cardiogenic shock, culprit-only PCI with staged completion reduced 30-day death or RRT compared with immediate multivessel PCI.RR 0.83Read →
- 2001TACTICS-TIMI 18Cardiology · Coronary · early invasive strategyIn 2,220 patients with NSTE-ACS treated with tirofiban, an early invasive strategy reduced 6-month death, MI, or rehospitalisation for ACS compared with a conservative strategy.OR 0.7895% CI 0.62-0.97Read →
Antiplatelet therapy around PCI4
- 2013WOESTCardiology · Thrombosis · AF + PCIIn 573 patients on oral anticoagulation undergoing PCI, clopidogrel without aspirin reduced bleeding compared with triple therapy.HR 0.36Read →
- 2009PLATO CoreCardiology · Coronary · AntiplateletsIn 18,624 patients hospitalised with ACS, ticagrelor reduced CV death, MI or stroke compared with clopidogrel, with similar major bleeding.HR 0.84Read →
- 2007TRITON-TIMI 38Cardiology · Coronary · AntiplateletsIn 13,608 ACS patients undergoing planned PCI, prasugrel reduced ischaemic events but increased major bleeding relative to clopidogrel.HR 0.81Read →
- 2001CURE CoreCardiology · Coronary · AntiplateletsIn 12,562 patients with NSTE-ACS, clopidogrel plus aspirin reduced the composite of CV death, MI or stroke versus aspirin alone.RR 0.8Read →
Cited landmark trials not yet in the register6
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2015BEST
PCI with everolimus-eluting stents versus CABG in multivessel disease — surgery superior.
- 2015MATRIX
Radial versus femoral access in acute coronary syndromes — fewer bleeds and deaths.
- 2016ART
Bilateral versus single internal thoracic artery grafting — no survival benefit at 10 years.
- 2015PRAMI / DANAMI-3-PRIMULTI
Complete versus culprit-only revascularisation in STEMI.
- 2009BARI 2D
Revascularisation versus medical therapy in diabetes with stable coronary disease.
- 2012IABP-SHOCK II
Intra-aortic balloon pump gave no survival benefit in infarct-related cardiogenic shock.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.